N-苄氧羰基-L-谷氨酸-5-甲酯 | 4652-65-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-苄氧羰基-L-谷氨酸-5-甲酯
• 中文别名: 5-甲基-N-Cbz-L-谷氨酸酯
• 英文名称: 4(S)-carboxy-4-(N-benzyloxycarbonylamino)butanoic acid methyl ester
• 英文别名: Z-Glu(OMe)-OH；methyl D,L-Z-glutamate；5-methoxy-5-oxo-2-(phenylmethoxycarbonylamino)pentanoic acid
• CAS: 4652-65-7
• 化学式: C₁₄H₁₇NO₆
• 分子量: 295.292
• InChiKey: JSNVOAWDAFVIKY-UHFFFAOYSA-N

物化性质

• 熔点：
  76℃
• 沸点：
  510.6±50.0 °C(Predicted)
• 密度：
  1.272±0.06 g/cm3(Predicted)
• 溶解度：
  溶于甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1-chloromethyl-9-methoxy-3-oxo-3H-benzo[f]benzopyran 、 N-苄氧羰基-L-谷氨酸-5-甲酯 在 potassium fluoride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以76%的产率得到5-methyl 1-(9-methoxy-3-oxo-3H-benzo[f]benzopyran-1-yl)methyl 2-((N-benzyloxycarbonyl)amino)pentanedioate
  参考文献：
  名称：

  Neurotransmitter amino acid—oxobenzo[f]benzopyran conjugates: synthesis and photorelease studies

  摘要：

  A series of fluorescent conjugates of neurotransmitter amino acids, such as P-alanine, tyrosine, 3,4-dihydroxyplienylalanine (DOPA) and glutamic acid, were prepared by reaction with a suitable fluorophore, namely 1-chloromethyl-9-methoxy-3-oxo-3H-benzo[f]benzopyran. The photophysical properties of the resulting ester bioconjugates were evaluated as well as the stability to photolysis at different wavelengths of irradiation (250, 300, 350 and 419 nm). (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2008.09.050
• 作为产物：
  描述：

  氯甲酸苄酯 、 2-氨基-5-氧代-5-甲氧基-戊酸 在 碳酸氢钠 作用下， 以 水 、 乙酸乙酯 为溶剂， 生成 N-苄氧羰基-L-谷氨酸-5-甲酯
  参考文献：
  名称：

  1-Hydroxy-3-amino-2-piperidone (.delta.-N-hydroxycycloornithine) derivatives: key intermediates for the synthesis of hydroxamate-based siderophores

  摘要：

  DOI：

  10.1021/jo00293a010

文献信息

• Preparation method for pyrrolidine-2-carboxylic acid derivatives
  申请人：ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD.

  公开号：US20160145208A1

  公开（公告）日：2016-05-26

  The present invention relates to the field of medical synthesis, in particular to a preparation method for pyrrolidine-2-carboxylic acid derivatives. The present invention adopts the following technical solution: providing a compound having a structure of formula (E), wherein R is R 1 or R 2 , R 1 is C 1 -C 6 an alkyl, benzyl, p-methoxybenzyl, or p-nitrobenzyl group, and R 2 is hydrogen; R 3 is a protecting group of the carboxyl group; and P 1 is a protecting group on nitrogen.

  本发明涉及医药合成领域，特别是一种吡咯烷-2-羧酸衍生物的制备方法。本发明采用以下技术方案：提供具有结构式（E）的化合物，其中R为R1或R2，R1为C1-C6烷基、苄基、对甲氧基苄基或对硝基苄基，R2为氢；R3为羧基的保护基；P1为氮上的保护基。
• [EN] METHOD FOR PREPARING 3-[(3S)-7-BROMO-2-OXO-5-(PYRIDIN-2-YL)-2,3-DIHYDRO-1H-[1,4]-BENZODIAZEPIN-3-YL] PROPIONIC ACID METHYL ESTER, AND COMPOUNDS USEFUL IN THAT METHOD<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ESTER MÉTHYLIQUE D'ACIDE 3-[(3S)-7-BROMO-2-OXO-5-(PYRIDIN-2-YL)-2,3-DIHYDRO-1H-[1,4]-BENZODIAZÉPIN-3-YL] PROPIONIQUE, ET COMPOSÉS UTILES DANS CE PROCÉDÉ
  申请人：MOEHS IBERICA SL

  公开号：WO2019020790A1

  公开（公告）日：2019-01-31

  The present invention relates to a method for preparing 3-[(3S)-7- bromo-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-IH-[l,4]-benzodiazepin-3-yl] propionic acid methyl ester from (2-amino-5-bromo-phenyl)-pyridin-2- yl-methanone. The present invention also relates to new compounds useful as intermediates in that method, methyl (4S)-4-amino-5-[4- bromo-2-(pyridin-2-carbonyl)anilino]-5-oxo-pentanoate hydrobromide salt and methyl (4S)-4-(benzyloxycarbonylamino)-5-[4-bromo-2- (pyridin-2-carbonyl)anilino]-5-oxo-pentanoate.

  本发明涉及一种从(2-氨基-5-溴苯基)-吡啶-2-基甲酮制备3-[(3S)-7-溴-2-氧-5-(吡啶-2-基)-2,3-二氢-IH-[1,4]-苯二氮杂环己-3-基]丙酸甲酯的方法。本发明还涉及作为该方法中间体有用的新化合物，即甲酸甲酯(4S)-4-氨基-5-[4-溴-2-(吡啶-2-甲酰基)苯胺基]-5-氧代-戊酸氢溴酸盐和甲酸甲酯(4S)-4-(苄氧羰基氨基)-5-[4-溴-2-(吡啶-2-甲酰基)苯胺基]-5-氧代-戊酸甲酯。
• [EN] METHOD FOR PREPARING 3-[(4S)-8-BROMO-1-METHYL-6-(PYRIDIN-2-YL)-4H-IMIDAZO[1,2-A][1,4]BENZODIAZEPIN-4-YL]-PROPIONIC ACID METHYL ESTER, AND COMPOUNDS USEFUL IN SAID METHOD<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ESTER MÉTHYLIQUE D'ACIDE 3-[(4S)-8-BROMO-1-MÉTHYL-6-(PYRIDIN-2-YL)-4H-IMIDAZO[1,2-A][1,4]BENZODIAZÉPIN-4-YL]-PROPIONIQUE, ET COMPOSÉS UTILES DANS LEDIT PROCÉDÉ
  申请人：MOEHS IBERICA SL

  公开号：WO2019072944A1

  公开（公告）日：2019-04-18

  The present invention relates to a method for preparing 3- [ ( 4S ) -8-bromo-l-methyl-6- (pyridin-2-yl ) -4H-imidazo [1,2- a] [ 1, 4 ] benzodiazepin-4-yl ] -propionic acid methyl ester starting from 3- [ (3S) -7-bromo-2-oxo-5- (pyridin-2-yl ) -2, 3-dihydro-lH- [ 1, 4 ] -benzodiazepin-3-yl ] propionic acid methyl ester, and novel compounds useful as intermediates in said method, i.e., (3S) -3- [ 7-bromo-2- ( 2, 2-dimethoxypropylamino ) -5-pyridin-2-yl-3H- benzo [e] [ 1, 4 ] diazepin-3-yl ] propionic acid methyl ester.

  本发明涉及一种制备3-[(4S)-8-溴-1-甲基-6-(吡啶-2-基)-4H-咪唑[1,2-a][1,4]苯二氮杂环己酮-4-基]-丙酸甲酯的方法，从3-[(3S)-7-溴-2-氧代-5-(吡啶-2-基)-2,3-二氢-1H-[1,4]-苯并二氮杂环己酮-3-基]-丙酸甲酯出发，以及在该方法中作为中间体有用的新化合物，即(3S)-3-[7-溴-2-(2,2-二甲氧基丙胺基)-5-吡啶-2-基-3H-苯并[e][1,4]二氮杂环己酮-3-基]-丙酸甲酯。
• Thiazole derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06344562B1

  公开（公告）日：2002-02-05

  Compounds of the formula: as well as pharmaceutically usable salts and esters thereof, wherein R1, R2 and R3 have the significance ascribed herein, inhibit binding of adhesive proteins to the surface of different types of cell and accordingly influence cell-cell and cell-matrix interactions. These compounds can be used in the form of pharmaceutical preparations for the control or prevention of neoplasms, tumor metastasing, tumor growth, osteoporosis, Paget's disease, diabetic retinopathy, macular degeneration, restenosis following vascular intervention, psoriasis, arthritis, fibrosis, kidney failure, as well as infection caused by viruses, bacteria or fungi.

  该公式的化合物：以及其药用盐和酯，其中R1、R2和R3具有在此规定的意义，抑制粘附蛋白质与不同类型细胞表面的结合，从而影响细胞-细胞和细胞-基质相互作用。这些化合物可以用作制药制剂的形式，用于控制或预防肿瘤、肿瘤转移、肿瘤生长、骨质疏松症、帕盖特病、糖尿病视网膜病变、黄斑变性、血管介入后再狭窄、银屑病、关节炎、纤维化、肾功能衰竭，以及由病毒、细菌或真菌引起的感染。
• [EN] SERINE REPLACEMENT POLYMYXIN ANALOGUES USEFUL AS ANTIBIOTIC POTENTIATORS<br/>[FR] ANALOGUES DE POLYMYXINE DE REMPLACEMENT DE SÉRINE UTILES EN TANT QUE POTENTIALISATEURS D'ANTIBIOTIQUE
  申请人：SPERO OPCO

  公开号：WO2017189868A1

  公开（公告）日：2017-11-02

  The disclosure provides compounds of the formula I or a tautomer thereof, or a pharmaceutically acceptable salt of either of the foregoing. The variables R1 and R2 are defined in the disclosure. The disclosure further includes pharmaceutical compositions comprising a compound of formula I together with at least one pharmaceutically acceptable carrier. The disclosure also includes a method of sensitizing bacteria to an antibacterial agent, comprising administering a therapeutically effective amount of the antibacterial agent and a compound of formula I to a patient infected with the bacteria, simultaneously or sequentially.

  该披露提供了公式I或其互变异构体的化合物，或者是上述任一化合物的药用盐。变量R1和R2在披露中有定义。该披露还包括包括公式I化合物以及至少一种药用载体的药物组合物。该披露还包括一种使细菌对抗菌剂敏感的方法，包括向感染有该细菌的患者同时或顺序地给予抗菌剂和公式I化合物的治疗有效量。